Cytosorbents Corp
Close on Oct 19, 2026
- Market cap
- $311.52M
- P/E (TTM)
- –
- Dividend yield
- –
About Cytosorbents
Surgical & Medical Instruments & Apparatus, SIC 3841
CytoSorbents Corporation develops and commercializes blood purification technologies designed to treat life-threatening conditions in intensive care units and cardiac surgery. Its core platform utilizes porous polymer beads inside cartridges to capture and filter toxic substances, cytokines, and drugs from blood and bodily fluids. The company’s commercial offerings include CytoSorb, an extracorporeal cytokine adsorber for critical illness and cardiac surgery; ECOS-300CY, an ex vivo organ perfusion cartridge for transplant preservation; VetResQ for animal emergency care; and the PuriFi hemoperfusion pump. The firm also develops the investigational DrugSorb-ATR system for antithrombotic removal. CytoSorbents serves hospitals, critical care facilities, and veterinary practices.
The company operates internationally, with its flagship CytoSorb cartridge distributed in more than 70 countries worldwide and approved in the European Union. CytoSorbents maintains commercial and distribution partnerships across multiple countries, including France, Poland, Sweden, Denmark, Norway, the Czech Republic, Finland, South Korea, Mexico, Colombia, Ecuador, and Italy. CytoSorbents maintains its executive offices in Princeton, New Jersey.
Summary of the business section of Cytosorbents's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cytosorbents Corp
- Headquarters
- Princeton, NJ
- Address
- 305 College Road East 08540
- Phone
- (973) 329-8885
- Website
- cytosorbents.com
- Employees
- 129, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- WithumSmith+Brown, PC, East Brunswick, New Jersey
Stock & identifiers
- Ticker
- CTSO
- Exchange
- Nasdaq
- IPO date
- Aug 8, 2006
- Shares outstanding
- 63M, Jul 31, 2026
- Public float
- $60.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Sep 8, 2026; 1-for-25 reverse, Dec 5, 2014; 1-for-25 reverse, Dec 3, 2014
- SEC CIK
- 1175151
- CUSIP
- 23283X206
- ISIN
- US23283X2062
- LEI
- 549300VI8WO8GK5QK793
- EIN
- 98-0373793
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Phillip P. Chan | Chief Executive Officer, Director | 100,996 |
| Vincent Capponi | President and COO | 40,114 |
| Peter J. Mariani | Chief Financial Officer | 638,113 |
| Efthymios Deliargyris | Chief Medical Officer | 473,025 |
| Alan D. Sobel | Director | 11,787 |
| Jiny Kim | Director | 77,819 |
| Edward Raymond Jones | Director | 88,834 |
| Michael G. Bator | Director | 151,273 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr.Phillip P. Chan | $808.43K | $723.16K | $679.23K | $12 | – |
| FY2024 Dr.Phillip P. Chan | $899.70K | $953.14K | $895.56K | $17 | – |
| FY2023 Dr.Phillip P. Chan | $1.33M | $729.76K | $994.69K | $20 | – |
| FY2022 Dr.Phillip P. Chan | $1.11M | $1.01M | $947.39K | $28 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of the issuance date of this Annual Report on Form 10-K, we had 129 employees.”
Corporate history
Events identified from SEC filings